Nurix Therapeutics, Inc. NRIX

23.08 (0.57) (2.41%) as of 25 Sep
Market cap
$2.5B
P/E
0.0×

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

May '26 Feb '26 Nov '25 Aug '25 Older periods
Net Income (89.53) (87.17) (78.22) (86.42)

+8 more quarters

Depreciation & Amortization 3.85 3.78 (5.69) 5.00
Non Cash Items (Other) 9.83 7.59 17.63 7.58
Accounts Payable Change 1.87 (0.46) 3.03 2.23
Change in payables and accrued liability (15.25) 4.12 11.04 6.34
Change in other assets and liabilities (7.34) 0.24 (15.62) (11.11)
Operating Cash Flow (96.57) (71.91) (67.83) (57.38)
Capital expenditures (1.94) (1.04) (5.13) (2.71)
Long-Term Investments Change (Net) 94.93 (122.78) 5.48 53.19
Investing cash flow 93.00 (123.83) 0.35 50.48
Equity Repurchase (Common, Net) 0.07 19.98 1.25 1.16
Other financial activities — — 234.76 —
Financing cash flow 0.07 19.98 236.01 1.16
Change in Cash (3.51) (175.76) 168.52 (5.75)
Beginning Cash 0.00 247.93 0.00 0.00
Ending Cash (3.51) 72.16 168.52 (5.75)
Stock Based Compensation 11.39 9.40 9.09 9.77
Dividends Paid (Common) 0.00 0.00 0.00 0.00
Net Cash/Marketcap 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total) (20.72) 3.90 (1.55) 16.46
Investments Change (Net) 94.93 (122.78) 5.48 53.19
Issuance/Purchase of Shares 0.07 19.98 1.25 1.16

Fold the line items

In millions of $ except per-share values · columns are period end dates